Not Signed In -
Tegaserod |
tegaserod maleate; Zelnorm |
Clinical Trial: Assessment of the Effect of Tegaserod (2 Mg Tid and 6 Mg Tid) on Dyspeptic Symptoms in Diabetic Patients with Symptoms of Diabethic Gastropathy
This study has been terminated.
|
Purpose
This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.
| Condition | Intervention | Phase |
|---|---|---|
| Diabetic Gastropathy | Drug: Tegaserod | Phase II |
MedlinePlus related topics: Diabetic Nerve Problems
Study Type: Interventional
Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Study start: May 2004
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
- GI symptoms for at least 2 months before entering study
Exclusion Criteria:
- Very high body weight
- Significant diarrhea
- Ulcers
Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.
Location Information
Switzerland
Novartis, Basel, 4056, Switzerland
Study chairs or principal investigators
Novartis, Study Chair, Basel
Novartis, Study Chair, Basel
More Information
Study ID Numbers: CHTF919G2203
Last Updated: September 1, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00142974
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06
Last Updated: September 1, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00142974
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06
email this page
print this page
bookmark this page
feedback on this page
